CTOR
Citius Oncology, Inc.
1W: -15.2%
1M: -47.9%
3M: -53.8%
YTD: -46.5%
1Y: -18.6%
$0.56
-0.02 (-3.81%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$51.0M
52W Range0.5306-6.19
Volume373,438
Avg Volume298,577
Beta3.04
Dividend—
Analyst Ratings
Company Info
CEOLeonard L. Mazur
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date2022-12-08
420 Lexington Avenue
New York City, NY 10170
US
New York City, NY 10170
US
347-627-0058
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Latest News
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% – Here’s What Happened
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HOLUBIAK MYRON Z | A-Award | 850,000 | — | 2025-09-19 |
| HOLUBIAK MYRON Z | A-Award | 100,000 | — | 2025-09-19 |
| Smith Robert Joseph | A-Award | 300,000 | — | 2025-09-19 |
| Mazur Leonard L | A-Award | 1,700,000 | — | 2025-09-19 |
| Webb Carol | A-Award | 300,000 | — | 2025-09-19 |